dysinosin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10439038 |
| CHEMBL ID | 502639 |
| MeSH ID | M0445070 |
| Synonym |
|---|
| bdbm50269776 |
| CHEMBL502639 , |
| dysinosin a |
| [(2r)-3-[[(2r)-1-[(2s,3ar,5s,6s,7as)-2-[2-[1-(diaminomethylidene)-2,5-dihydropyrrol-1-ium-3-yl]ethylcarbamoyl]-5,6-dihydroxy-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-2-methoxy-3-oxopropyl] sulfate |
| DTXSID001047314 |
Dysinosin A is a potent inhibitor of the blood coagulation cascade factor VIIa. It is also an inhibitors of the serine protease thrombin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dysinosin A is a potent inhibitor of the blood coagulation cascade factor VIIa and an inhibitor of the serine protease thrombin." | ( Dysinosin A: a novel inhibitor of Factor VIIa and thrombin from a new genus and species of Australian sponge of the family Dysideidae. Boström, SL; Carroll, AR; De Almeida Leone, P; Fechner, G; Hooper, JN; Hyde, E; Musil, D; Ngo, A; Pierens, GK; Quinn, RJ; Simpson, M, 2002) | 2.48 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prothrombin | Homo sapiens (human) | IC50 (µMol) | 0.0460 | 0.0000 | 0.7107 | 10.0000 | AID449340 |
| Prothrombin | Homo sapiens (human) | Ki | 0.4510 | 0.0000 | 0.7846 | 9.0000 | AID333059; AID425654 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 0.4520 | 0.0016 | 2.1212 | 9.0000 | AID333059 |
| Coagulation factor VII | Homo sapiens (human) | Ki | 0.1090 | 0.0002 | 1.5566 | 9.0000 | AID333058; AID425656 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lipopolysaccharide binding | Prothrombin | Homo sapiens (human) |
| serine-type endopeptidase activity | Prothrombin | Homo sapiens (human) |
| signaling receptor binding | Prothrombin | Homo sapiens (human) |
| calcium ion binding | Prothrombin | Homo sapiens (human) |
| protein binding | Prothrombin | Homo sapiens (human) |
| growth factor activity | Prothrombin | Homo sapiens (human) |
| heparin binding | Prothrombin | Homo sapiens (human) |
| thrombospondin receptor activity | Prothrombin | Homo sapiens (human) |
| serine-type endopeptidase activity | Coagulation factor VII | Homo sapiens (human) |
| signaling receptor binding | Coagulation factor VII | Homo sapiens (human) |
| calcium ion binding | Coagulation factor VII | Homo sapiens (human) |
| protein binding | Coagulation factor VII | Homo sapiens (human) |
| serine-type peptidase activity | Coagulation factor VII | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID333058 | Inhibition of factor 7a by spectrophotometric assay | 2004 | Journal of natural products, Aug, Volume: 67, Issue:8 | Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea. |
| AID425654 | Inhibition of thrombin | 2009 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14 | Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety. |
| AID333059 | Inhibition of thrombin by spectrophotometric assay | 2004 | Journal of natural products, Aug, Volume: 67, Issue:8 | Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea. |
| AID449340 | Inhibition of human thrombin | 2009 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18 | From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. |
| AID425656 | Inhibition of factor7a | 2009 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14 | Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||